Month: March 2011


Rising patient numbers and novel products are set to drive growth in the Chinese antidiabetics market

Melbourne, March 23, 2011 – Driven by the growing diabetic population and the improved healthcare insurance coverage implemented as part of the country's 2009 healthcare reform, the value of the overall diabetes drugs market in China will triple from $0.7bn in 2009 to $2.1bn in 2019, according to a new report from independent market analyst,…

25 Mar 2011, by Test1 Test1


The Chinese hepatitis B market is set to triple by 2019

Melbourne, March15, 2011 – Fueled by the world’s largest hepatitis B patient pool, uptake of new therapies such as PEGylated interferons and Viread (tenofovir), and the government’s latest healthcare reforms, the Chinese hepatitis B market is set to continue its recent growth, and to triple in size by 2019, according to the latest analysis by…

15 Mar 2011, by Test1 Test1


Battle against MRSA to net pharma industry US$2bn

Melbourne, 7th March 2011 - A number of new and expensive hospital brands targeting serious infections caused by multidrug-resistant bacteria, particularly MRSA*, will launch over the next decade. These will generate revenues totalling nearly US$2bn by 2019, according to independent market analyst Datamonitor.** However, the forecasted upside provided by these pipeline products will be insufficient…

7 Mar 2011, by Test1 Test1